NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM
Updated: May 26, 2022
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Kd
This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.
Sponsor
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03798678
Official Title: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
First Posted : January 10, 2019
Click here for details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Telaglenastat Hydrochloride
- Connecticut: Yale University New Haven
- Florida: Moffitt Cancer Center Tampa
- Minnesota: Mayo Clinic Rochester Minnesota
- New Jersey: Rutgers Cancer Institute of New Jersey New Brunswick
Locations
United States, Connecticut
United States, Florida
United States, Minnesota
United States, New Jersey
United States, Ohio